UPDATE: Piper Jaffray Downgrades XenoPort to Neutral on Drug Commercialization Delays
Piper Jaffray reduced its rating on XenoPort (NASDAQ: XNPT) from Overweight to Neutral with a reiterated $12 price target.
Piper Jaffray said, "Given the long road ahead for '829, our cautious view on the prospects for a partnership for '829 or outright sale of the company in the near-term and the lack of visibility on cash generation (i.e., continued lackluster prescription trends for Horizant and niche-like potential for arbaclofen placarbil for spasticity), we believe upside for XNPT shares is limited in the context of an enterprise value of $430M."
XenoPort closed at $11.91 on Thursday.
Latest Ratings for XNPT
|Jan 2016||Credit Suisse||Maintains||Underperform|
|Jan 2016||Credit Suisse||Initiates Coverage on||Underperform|
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.